NLS Clinical trials

Discover the richness of Latin America Biolatam is the biotechnology conference which provides unique access to Latin America, one of the fastest growing life science markets, in a forum for collaboration, discussion and partnering among key industry executives in Latin America, the US and Europe. International drug developers are increasingly targeting Latin America’s emerging market […]

This year’s Outsourcing in Clinical Trials Nordics conference covered a range of current topics in the clinical and medical device trial industry. At the beginning of September this year, CEOs, Chief Medical Officers and Clinical Directors met in Copenhagen to discuss current matters within outsourcing in clinical trials. The Outsourcing in Clinical Trials Nordics (OCT […]

Analysts and academics have begun discussing the possibility of using real-world data (RWD) for assessing the efficacy and safety of certain products, instead of always relying on the popular randomized controlled trials (RCT). “Data’s role in normal clinical practices, or in settings that reflect the reality of healthcare delivery, is likely to become increasingly important […]

A multi-center open label Phase 1b trial of BerGenBio AS’s BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway. The study is conducted at the University of Texas MD Anderson Cancer Center, […]

AstraZeneca PLC has created a scientific review board to assess requests from external researchers to access patient-level data.  The board of independent clinicians and academics has been developed as a part of the company’s commitment to groups including the European Federation of Pharmaceutical Industries and Associations, Pharmaceutical Research and Manufacturers of America Responsible Data Sharing […]

Danish biotech company  Orphazyme raised a €20 million ($24 million US) B round to pay for its work on rare lysosomal storage disorders as it moves toward Phase II trials. Investors included Novo Nordisk’s venture arm. Orphazyme’s lead candidate, Orph002, is a treatment for Niemann-Pick disease type C (NPC), a rare disorder in which cholesterol […]